161 related articles for article (PubMed ID: 35810936)
61. Risk stratification for cervical precancer and cancer by DH3-HPV partial genotyping and cytology in women attending cervical screening: A retrospective cohort study.
Fu Y; Li Y; Li X; Wang X; Lü W
J Med Virol; 2023 Feb; 95(2):e28482. PubMed ID: 36609841
[TBL] [Abstract][Full Text] [Related]
62. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer.
Castle PE; Fetterman B; Thomas Cox J; Shaber R; Poitras N; Lorey T; Kinney W
Obstet Gynecol; 2010 Jul; 116(1):76-84. PubMed ID: 20567171
[TBL] [Abstract][Full Text] [Related]
63. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
Zhang H; Varma KR; Han M; Matsko J; Zhao C
Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
[TBL] [Abstract][Full Text] [Related]
64. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
[TBL] [Abstract][Full Text] [Related]
65. Cytology compared with Hybrid Capture 2 human papilloma virus cervical cancer screening in HIV positive and HIV negative South African women.
Snyman LC; Richter KL; Lukhwareni A; Dreyer G; Botha MH; Van Der Merwe FH; Visser C; Dreyer G
Int J Gynecol Cancer; 2023 May; 33(5):669-675. PubMed ID: 36650011
[TBL] [Abstract][Full Text] [Related]
66. Screening capacity and cost-effectiveness of the human papillomavirus test versus cervicography as an adjunctive test to Pap cytology to detect high-grade cervical dysplasia.
Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():112-116. PubMed ID: 30682600
[TBL] [Abstract][Full Text] [Related]
67. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months.
Bulk S; Bulkmans NW; Berkhof J; Rozendaal L; Boeke AJ; Verheijen RH; Snijders PJ; Meijer CJ
Int J Cancer; 2007 Jul; 121(2):361-7. PubMed ID: 17354241
[TBL] [Abstract][Full Text] [Related]
68. The PapilloCheck Assay for Detection of High-Grade Cervical Intraepithelial Neoplasia.
Crosbie EJ; Bailey A; Sargent A; Gilham C; Peto J; Kitchener HC
J Clin Microbiol; 2015 Nov; 53(11):3553-9. PubMed ID: 26338859
[TBL] [Abstract][Full Text] [Related]
69. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.
Ronco G; Segnan N; Giorgi-Rossi P; Zappa M; Casadei GP; Carozzi F; Dalla Palma P; Del Mistro A; Folicaldi S; Gillio-Tos A; Nardo G; Naldoni C; Schincaglia P; Zorzi M; Confortini M; Cuzick J;
J Natl Cancer Inst; 2006 Jun; 98(11):765-74. PubMed ID: 16757701
[TBL] [Abstract][Full Text] [Related]
70. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial.
Kitchener HC; Gilham C; Sargent A; Bailey A; Albrow R; Roberts C; Desai M; Mather J; Turner A; Moss S; Peto J
Eur J Cancer; 2011 Apr; 47(6):864-71. PubMed ID: 21334200
[TBL] [Abstract][Full Text] [Related]
71. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
[TBL] [Abstract][Full Text] [Related]
72. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial.
Denny L; Kuhn L; Hu CC; Tsai WY; Wright TC
J Natl Cancer Inst; 2010 Oct; 102(20):1557-67. PubMed ID: 20884893
[TBL] [Abstract][Full Text] [Related]
73. Impact of HPV testing in opportunistic cervical screening: Support for primary HPV screening in the United States.
Cuzick J; Adcock R; Kinney W; Castle PE; Robertson M; McDonald RM; Stoler MH; Du R; Wheeler CM;
Int J Cancer; 2023 Jul; 153(1):83-93. PubMed ID: 36946690
[TBL] [Abstract][Full Text] [Related]
74. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
Tay SK; Lin LE; Goh RC
Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
[TBL] [Abstract][Full Text] [Related]
75. [Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].
Ronco G; Confortini M; Maccallini V; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Giorgi Rossi P
Epidemiol Prev; 2012; 36(5 Suppl 2):e1-e33. PubMed ID: 23139163
[TBL] [Abstract][Full Text] [Related]
76. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.
Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J
PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283
[TBL] [Abstract][Full Text] [Related]
77. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
[No Abstract] [Full Text] [Related]
78. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
[TBL] [Abstract][Full Text] [Related]
79. The combined finding of HPV 16, 18, or 45 and cytologic Atypical Glandular Cells (AGC) indicates a greatly elevated risk of in situ and invasive cervical adenocarcinoma.
Schiffman M; Mirabello L; Egemen D; Befano B; Xiao Y; Wentzensen N; Raine-Bennett T; Nayar R; Cheung LC; Rositch A; Beaty T; Perkins RB; de Sanjose S; Lorey T; Castle PE; Burk RD
Gynecol Oncol; 2023 Jul; 174():253-261. PubMed ID: 37243996
[TBL] [Abstract][Full Text] [Related]
80. Comparison of visual inspection with acetic acid and cervical cytology to detect high-grade cervical neoplasia among HIV-infected women in India.
Sahasrabuddhe VV; Bhosale RA; Kavatkar AN; Nagwanshi CA; Joshi SN; Jenkins CA; Shepherd BE; Kelkar RS; Sahay S; Risbud AR; Vermund SH; Mehendale SM
Int J Cancer; 2012 Jan; 130(1):234-40. PubMed ID: 21387289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
